The combination of CUDC-907 and gilteritinib shows promising in vitro and in vivo antileukemic activity against FLT3-ITD AML
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
The combination of CUDC-907 and gilteritinib shows promising in vitro and in vivo antileukemic activity against FLT3-ITD AML
Authors
Keywords
-
Journal
Blood Cancer Journal
Volume 11, Issue 6, Pages -
Publisher
Springer Science and Business Media LLC
Online
2021-06-07
DOI
10.1038/s41408-021-00502-7
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Cancer Statistics, 2021
- (2021) Rebecca L. Siegel et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Antileukemic activity and mechanism of action of the novel PI3K and histone deacetylase dual inhibitor CUDC-907 in acute myeloid leukemia
- (2019) Xinyu Li et al. HAEMATOLOGICA
- Inhibition of Bcl-2 Synergistically Enhances the Antileukemic Activity of Midostaurin and Gilteritinib in Preclinical Models of FLT3-mutated Acute Myeloid Leukemia
- (2019) Jun Ma et al. CLINICAL CANCER RESEARCH
- Gilteritinib or Chemotherapy for Relapsed or Refractory FLT3-Mutated AML
- (2019) Alexander E. Perl et al. NEW ENGLAND JOURNAL OF MEDICINE
- Targeting PI3K, mTOR, ERK, and Bcl-2 signaling network shows superior antileukemic activity against AML ex vivo
- (2018) Yongwei Su et al. BIOCHEMICAL PHARMACOLOGY
- Glutaminolysis is a metabolic dependency in FLT3ITDacute myeloid leukemia unmasked by FLT3 tyrosine kinase inhibition
- (2018) Paolo Gallipoli et al. BLOOD
- Cancer statistics, 2018
- (2018) Rebecca L. Siegel et al. CA-A CANCER JOURNAL FOR CLINICIANS
- ASP2215 in the treatment of relapsed/refractory acute myeloid leukemia with FLT3 mutation: background and design of the ADMIRAL trial
- (2018) Claudia M Gorcea et al. Future Oncology
- The Role for Myc in Coordinating Glycolysis, Oxidative Phosphorylation, Glutaminolysis, and Fatty Acid Metabolism in Normal and Neoplastic Tissues
- (2018) Eric S. Goetzman et al. Frontiers in Endocrinology
- Inhibition of XPO1 enhances cell death induced by ABT-199 in acute myeloid leukaemia via Mcl-1
- (2018) Daniel A. Luedtke et al. JOURNAL OF CELLULAR AND MOLECULAR MEDICINE
- Pharmacometabolomics Reveals Irinotecan Mechanism of Action in Cancer Patients
- (2018) Xun Bao et al. JOURNAL OF CLINICAL PHARMACOLOGY
- CUDC-907 in relapsed/refractory diffuse large B-cell lymphoma, including patients with MYC-alterations: results from an expanded phase I trial
- (2017) Yasuhiro Oki et al. HAEMATOLOGICA
- Selective inhibition of FLT3 by gilteritinib in relapsed or refractory acute myeloid leukaemia: a multicentre, first-in-human, open-label, phase 1–2 study
- (2017) Alexander E Perl et al. LANCET ONCOLOGY
- FLT3 Inhibitors in Acute Myeloid Leukemia: Current Status and Future Directions
- (2017) Maria Larrosa-Garcia et al. MOLECULAR CANCER THERAPEUTICS
- FLT3-ITD induces expression of Pim kinases through STAT5 to confer resistance to the PI3K/Akt pathway inhibitors on leukemic cells by enhancing the mTORC1/Mcl-1 pathway
- (2017) Keigo Okada et al. Oncotarget
- CUDC-907 in relapsed/refractory diffuse large B-cell lymphoma, including patients with MYC-alterations: results from an expanded phase I trial
- (2017) Yasuhiro Oki et al. HAEMATOLOGICA
- Mechanisms responsible for the synergistic antileukemic interactions between ATR inhibition and cytarabine in acute myeloid leukemia cells
- (2017) Jun Ma et al. Scientific Reports
- Preclinical studies of gilteritinib, a next-generation FLT3 inhibitor
- (2016) Lauren Y. Lee et al. BLOOD
- FGF2 from Marrow Microenvironment Promotes Resistance to FLT3 Inhibitors in Acute Myeloid Leukemia
- (2016) Elie Traer et al. CANCER RESEARCH
- Molecular Pathways: AXL, a Membrane Receptor Mediator of Resistance to Therapy
- (2016) M. Scaltriti et al. CLINICAL CANCER RESEARCH
- Safety, tolerability, and preliminary activity of CUDC-907, a first-in-class, oral, dual inhibitor of HDAC and PI3K, in patients with relapsed or refractory lymphoma or multiple myeloma: an open-label, dose-escalation, phase 1 trial
- (2016) Anas Younes et al. LANCET ONCOLOGY
- MYC and metabolism on the path to cancer
- (2015) Annie L. Hsieh et al. SEMINARS IN CELL & DEVELOPMENTAL BIOLOGY
- MYC, Metabolism, and Cancer
- (2015) Z. E. Stine et al. Cancer Discovery
- Acute myeloid leukemia cells harboring MLL fusion genes or with the acute promyelocytic leukemia phenotype are sensitive to the Bcl-2-selective inhibitor ABT-199
- (2014) X Niu et al. LEUKEMIA
- Axl, a prognostic and therapeutic target in acute myeloid leukemia mediates paracrine crosstalk of leukemia cells with bone marrow stroma
- (2013) I. Ben-Batalla et al. BLOOD
- Bone marrow stroma-mediated resistance to FLT3 inhibitors in FLT3-ITD AML is mediated by persistent activation of extracellular regulated kinase
- (2013) Xiaochuan Yang et al. BRITISH JOURNAL OF HAEMATOLOGY
- Panobinostat Enhances Cytarabine and Daunorubicin Sensitivities in AML Cells through Suppressing the Expression of BRCA1, CHK1, and Rad51
- (2013) Chengzhi Xie et al. PLoS One
- How I treat pediatric acute myeloid leukemia
- (2012) J. E. Rubnitz BLOOD
- Axl-dependent signalling: a clinical update
- (2011) Vyacheslav A. Korshunov CLINICAL SCIENCE
- Targeting the translational apparatus to improve leukemia therapy: roles of the PI3K/PTEN/Akt/mTOR pathway
- (2011) A M Martelli et al. LEUKEMIA
- Mechanisms of Synergistic Antileukemic Interactions between Valproic Acid and Cytarabine in Pediatric Acute Myeloid Leukemia
- (2010) C. Xie et al. CLINICAL CANCER RESEARCH
- Discovery of 5-Chloro-N2-[(1S)-1-(5-fluoropyrimidin-2-yl)ethyl]-N4-(5-methyl-1H-pyrazol-3-yl)pyrimidine-2,4-diamine (AZD1480) as a Novel Inhibitor of the Jak/Stat Pathway
- (2010) Stephanos Ioannidis et al. JOURNAL OF MEDICINAL CHEMISTRY
- Ubiquitin conjugase UBCH8 targets active FMS-like tyrosine kinase 3 for proteasomal degradation
- (2010) M Buchwald et al. LEUKEMIA
- FLT3-ITD up-regulates MCL-1 to promote survival of stem cells in acute myeloid leukemia via FLT3-ITD-specific STAT5 activation
- (2009) G. Yoshimoto et al. BLOOD
- Bim Upregulation by Histone Deacetylase Inhibitors Mediates Interactions with the Bcl-2 Antagonist ABT-737: Evidence for Distinct Roles for Bcl-2, Bcl-xL, and Mcl-1
- (2009) S. Chen et al. MOLECULAR AND CELLULAR BIOLOGY
- c-Myc suppression of miR-23a/b enhances mitochondrial glutaminase expression and glutamine metabolism
- (2009) Ping Gao et al. NATURE
- MS-275, a novel histone deacetylase inhibitor with selectivity against HDAC1, induces degradation of FLT3 via inhibition of chaperone function of heat shock protein 90 in AML cells
- (2008) Chie Nishioka et al. LEUKEMIA RESEARCH
- Myc regulates a transcriptional program that stimulates mitochondrial glutaminolysis and leads to glutamine addiction
- (2008) D. R. Wise et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationPublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More